O4‐07‐02: ENRICHMENT OF EARLY‐STAGE AD PATIENT RECRUITMENT TO A PHASE IB STUDY (221AD103) THROUGH AMYLOID PET SCREENING BY APOE ɛ4 STATUS
Ping Chiao(Biogen (United States)), Jeff Sevigny(Ovid Therapeutics (United States)), Meredith Burke(Syntek Technologies (United States)), Joyce Suhy(BioClinica (United States)), Gregory Klein(Roche (Switzerland)), Ajay Verma(Biogen (United States)), Jerome Barakos(Sutter Health)
Cited by 1
Related Papers
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
|Neurology|2009|741
11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
|The Lancet Neurology|2010|696
Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease
|JAMA Neurology|2021|602
A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
|Alzheimer s Research & Therapy|2017|568